🚨 $CVKD
Amendment to 2022 Successor Equity Incentive Plan On September 24, 2026, Cadrenal Therapeutics, Inc. , held its 2026 Annual Meeting of Stockholders . At the 2026 Annual Meeting, the Company’s stockholders approved an amendment to the Company’s 2022 Successor Equity Incentive Plan, as amen...
Amendment to 2022 Successor Equity Incentive Plan On September 24, 2026, Cadrenal Therapeutics, Inc. , held its 2026 Annual Meeting of Stockholders . At the 2026 Annual Meeting, the Company’s stockholders approved an amendment to the Company’s 2022 Successor Equity Incentive Plan, as amen...
SEC Filing: CVKD
Click to view the official SEC document.
www.sec.gov
September 29, 2026 at 8:06 PM
🚨 $CVKD
Amendment to 2022 Successor Equity Incentive Plan On September 24, 2026, Cadrenal Therapeutics, Inc. , held its 2026 Annual Meeting of Stockholders . At the 2026 Annual Meeting, the Company’s stockholders approved an amendment to the Company’s 2022 Successor Equity Incentive Plan, as amen...
Amendment to 2022 Successor Equity Incentive Plan On September 24, 2026, Cadrenal Therapeutics, Inc. , held its 2026 Annual Meeting of Stockholders . At the 2026 Annual Meeting, the Company’s stockholders approved an amendment to the Company’s 2022 Successor Equity Incentive Plan, as amen...
Join us on March 11-12 for the OTC Markets Life Sciences Virtual Investor Forum, featuring CEO chats and presentations from innovative companies, including: #$ICU #$BORAY #$MTVA #$AEMD #$DYAI #$XAIR #$CVKD
Register now: buff.ly/8n7kXxk
#investorconference #lifesciences
Register now: buff.ly/8n7kXxk
#investorconference #lifesciences
March 3, 2026 at 9:15 PM
Join us on March 11-12 for the OTC Markets Life Sciences Virtual Investor Forum, featuring CEO chats and presentations from innovative companies, including: #$ICU #$BORAY #$MTVA #$AEMD #$DYAI #$XAIR #$CVKD
Register now: buff.ly/8n7kXxk
#investorconference #lifesciences
Register now: buff.ly/8n7kXxk
#investorconference #lifesciences
$GCTK shifts capital to Lōkahi's asset acquisitions; Glucotrack stays on CGM, prioritizing LT-100 & expanding ai² for late-stage therapies. $ARTL $VTGN $BMEA $IMVT $JAGX $TLSA $CVKD $CGEM $SLXN
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
Daily Updates 09/23/26
export-download.canva.com
September 23, 2026 at 8:30 PM
$GCTK shifts capital to Lōkahi's asset acquisitions; Glucotrack stays on CGM, prioritizing LT-100 & expanding ai² for late-stage therapies. $ARTL $VTGN $BMEA $IMVT $JAGX $TLSA $CVKD $CGEM $SLXN
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
#$CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy buff.ly/qK8YuWf
August 3, 2026 at 8:18 PM
#$CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy buff.ly/qK8YuWf
🚀 Zacks Small Cap Research - CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-cvkd-positive-cad-1005-data-accelerates-transition-toward-business-development-strategy/
#Cadre<a href="/hashtag/Cadre" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Cadre
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-cvkd-positive-cad-1005-data-accelerates-transition-toward-business-development-strategy/
#Cadre<a href="/hashtag/Cadre" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Cadre
August 4, 2026 at 12:56 AM
🚀 Zacks Small Cap Research - CVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-cvkd-positive-cad-1005-data-accelerates-transition-toward-business-development-strategy/
#Cadre<a href="/hashtag/Cadre" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Cadre
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-cvkd-positive-cad-1005-data-accelerates-transition-toward-business-development-strategy/
#Cadre<a href="/hashtag/Cadre" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Cadre
как здесь, да
www.youtube.com/watch?v=cVKd...
www.youtube.com/watch?v=cVKd...
How FromSoftware-sexuals Expect You To Play Their Games
YouTube video by Cilvanis
www.youtube.com
July 2, 2025 at 12:17 PM
как здесь, да
www.youtube.com/watch?v=cVKd...
www.youtube.com/watch?v=cVKd...
Agnès Varda on making documentaries
YouTube video by lachambreverte
www.youtube.com
August 10, 2026 at 6:14 AM
#$CVKD OTC Markets Hosts Virtual Investor Presentation with Quang Pham, Chairman and CEO of Cadrenal Therapeutics, and David Bautz, PhD, Senior Analyst at Zacks SCR buff.ly/sBFmkfc
March 20, 2026 at 8:23 PM
#$CVKD OTC Markets Hosts Virtual Investor Presentation with Quang Pham, Chairman and CEO of Cadrenal Therapeutics, and David Bautz, PhD, Senior Analyst at Zacks SCR buff.ly/sBFmkfc
🚨 $CVKD
On May 28, 2026, Cadrenal Therapeutics, Inc. and Matthew K. Szot mutually agreed to his transition from the role of Chief Financial Officer, effective May 28, 2026. Effective immediately after Mr. Szot’s termination, the Company appointed Quang X. Pham, its Chief Executive Officer, as int...
On May 28, 2026, Cadrenal Therapeutics, Inc. and Matthew K. Szot mutually agreed to his transition from the role of Chief Financial Officer, effective May 28, 2026. Effective immediately after Mr. Szot’s termination, the Company appointed Quang X. Pham, its Chief Executive Officer, as int...
SEC Filing: CVKD
Click to view the official SEC document.
www.sec.gov
June 3, 2026 at 9:57 PM
🚨 $CVKD
On May 28, 2026, Cadrenal Therapeutics, Inc. and Matthew K. Szot mutually agreed to his transition from the role of Chief Financial Officer, effective May 28, 2026. Effective immediately after Mr. Szot’s termination, the Company appointed Quang X. Pham, its Chief Executive Officer, as int...
On May 28, 2026, Cadrenal Therapeutics, Inc. and Matthew K. Szot mutually agreed to his transition from the role of Chief Financial Officer, effective May 28, 2026. Effective immediately after Mr. Szot’s termination, the Company appointed Quang X. Pham, its Chief Executive Officer, as int...
You look like Superman trying to eye laser blast his own dick, which if I was Superman I would have tried to do on like five different occasions.
I think according to the lore this is actually how he has to manscape.
www.youtube.com/watch?v=cvkD...
I think according to the lore this is actually how he has to manscape.
www.youtube.com/watch?v=cvkD...
How Superman shaves
YouTube video by Bystander
www.youtube.com
November 6, 2024 at 4:00 AM
You look like Superman trying to eye laser blast his own dick, which if I was Superman I would have tried to do on like five different occasions.
I think according to the lore this is actually how he has to manscape.
www.youtube.com/watch?v=cvkD...
I think according to the lore this is actually how he has to manscape.
www.youtube.com/watch?v=cvkD...
#CVKD Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-5u6lllnwhs0e.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-5u6lllnwhs0e.html?utm_source=stocktitan-bluesky&utm_medium=social
An online investor conference will include Cadrenal Therapeutics Sept. 29
CEO Quang X. Pham will present at 10:15 a.m. ET Sept. 29; management will hold virtual one-on-one meetings through Sept. 30, with a replay afterward.
www.stocktitan.net
September 21, 2026 at 8:30 PM
#CVKD Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2026 Investor Conference
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-5u6lllnwhs0e.html?utm_source=stocktitan-bluesky&utm_medium=social
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-5u6lllnwhs0e.html?utm_source=stocktitan-bluesky&utm_medium=social
#CVKD #ABT Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-announces-collaboration-agreement-with-abbott-xulnyrifc6xo.html
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-announces-collaboration-agreement-with-abbott-xulnyrifc6xo.html
Can Cadrenal's Tecarfarin Revolutionize Treatment for HeartMate 3 LVAD Patients?
Abbott to provide expertise and support for Cadrenal's TECH-LVAD study evaluating tecarfarin in heart failure patients, targeting a $1.1B market with projected growth.
www.stocktitan.net
March 4, 2025 at 1:00 PM
#CVKD #ABT Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-announces-collaboration-agreement-with-abbott-xulnyrifc6xo.html
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-announces-collaboration-agreement-with-abbott-xulnyrifc6xo.html
#CVKD Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-launches-partnering-process-as-its-cardiac-9t32kq341jho.html
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-launches-partnering-process-as-its-cardiac-9t32kq341jho.html
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditions Company is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarin Recently presented Phase 2
www.stocktitan.net
July 21, 2026 at 12:00 PM
#CVKD Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-launches-partnering-process-as-its-cardiac-9t32kq341jho.html
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-launches-partnering-process-as-its-cardiac-9t32kq341jho.html
#CVKD Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-to-participate-in-h-c-wainwright-s-28th-annual-k5smoe6ei5a3.html
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-to-participate-in-h-c-wainwright-s-28th-annual-k5smoe6ei5a3.html
www.stocktitan.net
September 3, 2026 at 12:00 PM
#CVKD Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-to-participate-in-h-c-wainwright-s-28th-annual-k5smoe6ei5a3.html
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-to-participate-in-h-c-wainwright-s-28th-annual-k5smoe6ei5a3.html
$CANF’s Phase 3 HCC trial shows longer-than-expected survival in blinded data; early interim analysis planned. No efficacy conclusions yet. $CANF $TEVA $CDT $TCRX $UPC $PPBT $ALGS $CALC $CVKD $LABT
www.biopharmcatalyst.com/news/2026/la...
www.biopharmcatalyst.com/news/2026/la...
Pre-Market Updates 09/02/26
export-download.canva.com
September 2, 2026 at 12:40 PM
$CANF’s Phase 3 HCC trial shows longer-than-expected survival in blinded data; early interim analysis planned. No efficacy conclusions yet. $CANF $TEVA $CDT $TCRX $UPC $PPBT $ALGS $CALC $CVKD $LABT
www.biopharmcatalyst.com/news/2026/la...
www.biopharmcatalyst.com/news/2026/la...
🚀 Zacks Small Cap Research - CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-cvkd-advancing-partnering-process-for-cardiac-acute-critical-care-franchise/
#CadrenalT#CadrenalTherapeuticsa href="/hashtag/C" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#C href="/hashtag/CVKD" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#CVKD
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-cvkd-advancing-partnering-process-for-cardiac-acute-critical-care-franchise/
#CadrenalT#CadrenalTherapeuticsa href="/hashtag/C" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#C href="/hashtag/CVKD" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#CVKD
August 31, 2026 at 3:59 PM
🚀 Zacks Small Cap Research - CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-cvkd-advancing-partnering-process-for-cardiac-acute-critical-care-franchise/
#CadrenalT#CadrenalTherapeuticsa href="/hashtag/C" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#C href="/hashtag/CVKD" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#CVKD
🔎 Read the full update:
➡️https://theminingnews.com/zacks-small-cap-research-cvkd-advancing-partnering-process-for-cardiac-acute-critical-care-franchise/
#CadrenalT#CadrenalTherapeuticsa href="/hashtag/C" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#C href="/hashtag/CVKD" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#CVKD
BUY $CVKD (CVKD.O) [FDA] @ 12:00:03Z
August 31, 2026 at 12:00 PM
BUY $CVKD (CVKD.O) [FDA] @ 12:00:03Z
#$CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise buff.ly/XHVmx2H
August 31, 2026 at 3:06 PM
#$CVKD: Advancing Partnering Process for Cardiac Acute Critical Care Franchise buff.ly/XHVmx2H
🚨 JUST IN: $CVKD
Cadrenal gets FDA alignment on Phase 3 endpoint for CAD-1005 in HIT
#SEC #stocks #investing #CVKD #Regulatory
🔗 secwatch.observer
Cadrenal gets FDA alignment on Phase 3 endpoint for CAD-1005 in HIT
#SEC #stocks #investing #CVKD #Regulatory
🔗 secwatch.observer
August 31, 2026 at 1:23 PM
🚨 JUST IN: $CVKD
Cadrenal gets FDA alignment on Phase 3 endpoint for CAD-1005 in HIT
#SEC #stocks #investing #CVKD #Regulatory
🔗 secwatch.observer
Cadrenal gets FDA alignment on Phase 3 endpoint for CAD-1005 in HIT
#SEC #stocks #investing #CVKD #Regulatory
🔗 secwatch.observer
🚨 $CVKD
On August 31, 2026, Cadrenal Therapeutics, Inc. issued a press release announcing positive feedback from a Type D Meeting with the U.S. Food and Drug Administration held on July 28, 2026. During the meeting, the Company and the FDA aligned on key aspects of the protocol and Statistical An...
On August 31, 2026, Cadrenal Therapeutics, Inc. issued a press release announcing positive feedback from a Type D Meeting with the U.S. Food and Drug Administration held on July 28, 2026. During the meeting, the Company and the FDA aligned on key aspects of the protocol and Statistical An...
SEC Filing: CVKD
Click to view the official SEC document.
www.sec.gov
August 31, 2026 at 12:30 PM
🚨 $CVKD
On August 31, 2026, Cadrenal Therapeutics, Inc. issued a press release announcing positive feedback from a Type D Meeting with the U.S. Food and Drug Administration held on July 28, 2026. During the meeting, the Company and the FDA aligned on key aspects of the protocol and Statistical An...
On August 31, 2026, Cadrenal Therapeutics, Inc. issued a press release announcing positive feedback from a Type D Meeting with the U.S. Food and Drug Administration held on July 28, 2026. During the meeting, the Company and the FDA aligned on key aspects of the protocol and Statistical An...
#CVKD Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-announces-positive-outcome-from-fda-type-d-ugaeknprpwlm.html
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-announces-positive-outcome-from-fda-type-d-ugaeknprpwlm.html
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
Cadrenal Therapeutics (Nasdaq: CVKD) reported a positive outcome from a July 28, 2026 FDA Type D meeting on the Phase 3 registration study of CAD-1005, a first-in-class 12-lipoxygenase inhibitor in development for heparin-induced thrombocytopenia (HIT). The FDA and Cadrenal aligned on key elements of the protocol and Statistical Analysis Plan, including an optimized composite primary endpoint based on adjudicated new or worsening thromboembolic events in Serotonin Release Assay-positive patients through Day 14 or hospital discharge.According to Cadrenal Therapeutics, the FDA also agreed to a placebo-controlled design with standard anticoagulation in both arms and to assess bleeding as a major safety endpoint using International Society on Thrombosis and Haemostasis criteria, providing greater clarity on the regulatory path for CAD-1005’s Phase 3 program.
www.stocktitan.net
August 31, 2026 at 12:00 PM
#CVKD Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Thrombocytopenia
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-announces-positive-outcome-from-fda-type-d-ugaeknprpwlm.html
https://www.stocktitan.net/news/CVKD/cadrenal-therapeutics-announces-positive-outcome-from-fda-type-d-ugaeknprpwlm.html
🚨 $CVKD
(d) Exhibits The following exhibits are furnished with this Current Report on Form 8-K: Exhibit Number Exhibit Description 99.1 Press Release, issued by Cadrenal Therapeutics, Inc. on August 13, 2026 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the...
(d) Exhibits The following exhibits are furnished with this Current Report on Form 8-K: Exhibit Number Exhibit Description 99.1 Press Release, issued by Cadrenal Therapeutics, Inc. on August 13, 2026 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the...
SEC Filing: CVKD
Click to view the official SEC document.
www.sec.gov
August 13, 2026 at 8:51 PM
🚨 $CVKD
(d) Exhibits The following exhibits are furnished with this Current Report on Form 8-K: Exhibit Number Exhibit Description 99.1 Press Release, issued by Cadrenal Therapeutics, Inc. on August 13, 2026 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the...
(d) Exhibits The following exhibits are furnished with this Current Report on Form 8-K: Exhibit Number Exhibit Description 99.1 Press Release, issued by Cadrenal Therapeutics, Inc. on August 13, 2026 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the...